Dosing of First Patient in Phase 2a Clinical Trial of DA-1241 Expected September 2023
Cash and Cash Equivalents of $28.7 Million, Expected to Fund the Company into 2024, Through Multiple Clinical Milestones
Read more at prnewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Dosing of First Patient in Phase 2a Clinical Trial of DA-1241 Expected September 2023
Cash and Cash Equivalents of $28.7 Million, Expected to Fund the Company into 2024, Through Multiple Clinical Milestones
Read more at prnewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| NRBO | 2.36 | +0.01 | +0.43% |
| Neurobo Pharmaceuticals Inc | |||